ATG-F

DRUG3 trials

Sponsors

Hadassah Medical Organization, Astellas Pharma Inc, Centre Hospitalier Universitaire de Saint Etienne

Conditions

Allogeneic Haplo-Stem Cell Transplatation (SCT)De Novo Kidney Transplant PatientsGlomerulonephritisGraft Versus Host DiseaseIgAN

Phase 3

A Study to Evaluate the Effect of ATG-F on Engraftment, Graft Versus Host Disease (GVHD) and Graft Versus Leukemia (GVL) Effect in Haplo-identical SCT

TerminatedNCT00616954

Hadassah Medical OrganizationAllogeneic Haplo-Stem Cell Transplatation (SCT), Graft Versus Host Disease

Start: 2008-05-31End: 2010-09-30Target: 50Updated: 2015-04-21

Phase 4

Efficacy and Safety of Two Anti-T-lymphocyte Immune Globulin (ATG-F) Induction Regimens in Anew Kidney Transplant Patients

CompletedNCT02267512

Astellas Pharma IncDe Novo Kidney Transplant Patients

Start: 2012-07-31End: 2015-12-31Updated: 2024-11-01

Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment

TerminatedNCT02523768

Centre Hospitalier Universitaire de Saint EtienneGlomerulonephritis, IgAN

Start: 2011-01-08End: 2020-02-24Updated: 2021-01-20